STEP 5 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Archive — May 2026
Page 4 of 5 of this archive, newest first.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Calder Vale Peptides of Skipton closes after 5 years
A proper account of an operation that existed, and of what closing it cost.
Where the receptor is: a tissue-by-tissue account of liraglutide’s reach
The central effects are not a bonus. On the current evidence they are the principal mechanism of weight loss.
The upper rungs, ranked by evidence
Where the curve flattens, what flattens with it, and what does not.
Independent analysis puts a Homopeptide semaglutide lot at 98.1%, against 95.4% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
QSC names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The 6-day notice: how a compounding wind-down works in Argentina
The document is four pages. Three of them are about dates.
From the floor in Chengdu: 15 posters, one theme
Reported from the sessions, and from the two hours afterwards.
An error taxonomy for a market without a pharmacist
The recurring errors in this market are not exotic. They are a small set of arithmetic and reading failures, each capable of moving a dose by a factor of two or ten.
Choosing a needle for a subcutaneous peptide
Skin thickness at the standard injection sites is approximately two millimetres in adults and varies remarkably little with body mass. That single finding is why short…
Janoshik result on a Hangzhou cagrilintide lot lands 0.9 points above the supplier’s stated figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
What a 42% rise in coupling-reagent prices does to a 15 mg vial
Follow the resin, not the catalogue.
A shortage listing ends. 13 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of the consolidator trading as Meridian Freight Partners
A proper account of an operation that existed, and of what closing it cost.
Carbon-13, and the reason a peptide has more than one mass
A peptide has a monoisotopic mass and an average mass, they differ by several daltons at this molecular size, and a certificate that does not say which it quotes cannot be…
A reference interval is not a target, and a result outside one is not a diagnosis
The arithmetic of the reference change value, worked for the analytes that matter here.
The badge economy, and what it is actually certifying
Every step between the laboratory report and the product page removes information, and the badge is the last step.
Portugal pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
From the floor in Shanghai: 8 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Five things a purity figure cannot tell you
Aggregates dissociate in the mobile phase and are recorded as monomer. Only a size-based separation reports them.
The 27-day notice: how a compounding wind-down works in Spain
The document is four pages. Three of them are about dates.
LEADER extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The online reseller trading as Adamant Research Supply enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Aggregation: the impurity your chromatogram dissolved before it looked
We describe each pathway in enough chemical detail to explain why it is invisible to the method the trade uses, because that is the part which has practical consequences.
Side effects, cost, supply, target: four reasons with four trajectories
Why the reason for stopping changes what happens afterwards.
The United Kingdom pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
Shanghai export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Poland health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
The relabeller trading as Vantris Bio closes after 3 years
A proper account of an operation that existed, and of what closing it cost.
The supply gap as a clinical event
Why the reason for stopping changes what happens afterwards.
Beta-arrestin, cAMP, and the part of cagrilintide’s mechanism nobody quotes
Selectivity, potency and efficacy are three different measurements. The trade routinely reports none of them.
The 7-day notice: how a compounding wind-down works in Nigeria
The document is four pages. Three of them are about dates.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
We asked four laboratories for a sterility test. Here is what came back.
We asked all four services what they can determine, on what timescale, at what price, and under what accreditation. The answers are printed in full.
What STEP 4 and SURMOUNT-4 actually established
What the trials measured was continuation against withdrawal. What patients want to know is continuation at a lower dose, and that study has largely not been done.
New Zealand pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.